All In Biotech

Drug Trial Radar · NCT06979596

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Aug 11, 2025

Primary completion

Nov 4, 2027

Study completion Nov 4, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones. Researchers will compare MK-5684 to the standard treatments for each cancer type in this study. The goal of this study is to learn if people who receive MK-5684 live longer without the cancer growing or spreading compared to people who receive a standard treatment.

Conditions

  • Malignant Neoplasm

Interventions

  • OpevesostatDrug

    Tablet for oral administration.

  • Fludrocortisone/ Fludrocortisone acetateDrug

    Tablet for oral administration.

  • Dexamethasone/Dexamethasone acetateDrug

    Tablet for oral administration.

  • Rescue MedicationsDrug

    Hydrocortisone or hydrocortisone/hydrocortisone acetate administered via intramuscular injection as rescue medication.

  • FulvestrantDrug

    Administered via intramuscular injection.

  • ExemestaneDrug

    Tablet for oral administration.

  • Megestrol acetate/Medroxyprogesterone acetateDrug

    Tablet for oral administration.

  • TamoxifenDrug

    Tablet for oral administration.

  • LetrozoleDrug

    Tablet for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) - All CohortsTime frame: Up to approximately 2 years

Locations

60 sites in 13 countries. Site status is shown where the registry gives one.

  • Alaska Womens Cancer Care ( Site 0037)

    Anchorage, Alaska · Recruiting

  • Mount Sinai Cancer Center ( Site 0009)

    Miami Beach, Florida · Recruiting

  • TRIALS 365 ( Site 0022)

    Shreveport, Louisiana · Recruiting

  • Mary Lanning Healthcare ( Site 0019)

    Hastings, Nebraska · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0021)

    Hackensack, New Jersey · Recruiting

  • Rockefeller Outpatient Pavilion ( Site 0002)

    New York, New York · Recruiting

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0008)

    Columbus, Ohio · Recruiting

  • Baylor College of Medicine Medical Center ( Site 0004)

    Houston, Texas · Recruiting

  • Harris Health System ( Site 0040)

    Houston, Texas · Recruiting

  • Mays Cancer Center ( Site 0039)

    San Antonio, Texas · Recruiting

  • Hospital Aleman ( Site 0301)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Centro Medico Dr. Doreski - Fundación Respirar ( Site 0302)

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • Instituto Alexander Fleming ( Site 0303)

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • Instituto Nacional de Câncer - INCA ( Site 3107)

    Rio de Janeiro, Brazil · Recruiting

  • Hospital Santa Rita de Cassia ( Site 3104)

    Vitória, Espírito Santo, Brazil · Recruiting

  • Obras Sociais Irma Dulce ( Site 3112)

    Salvador, Estado de Bahia, Brazil · Recruiting

  • Hospital Felicio Rocho ( Site 3105)

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Hospital de Cancer de Pernambuco ( Site 3103)

    Recife, Pernambuco, Brazil · Recruiting

  • Liga Norte Riograndense Contra o Cancer ( Site 3108)

    Natal, Rio Grande do Norte, Brazil · Recruiting

  • Sunnybrook Research Institute ( Site 0203)

    Toronto, Ontario, Canada · Recruiting

  • Princess Margaret Cancer Centre ( Site 0202)

    Toronto, Ontario, Canada · Recruiting

  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0200)

    Montreal, Quebec, Canada · Recruiting

  • Jewish General Hospital ( Site 0201)

    Montreal, Quebec, Canada · Recruiting

  • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0205)

    Sherbrooke, Quebec, Canada · Recruiting

  • Fundación Arturo López Pérez ( Site 3300)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Pontificia Universidad Catolica de Chile ( Site 3307)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Bradfordhill ( Site 3301)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • ONCOCENTRO APYS ( Site 3302)

    Viña del Mar, Valparaiso, Chile · Recruiting

  • Pantai Hospital Kuala Lumpur ( Site 0603)

    Kuala Lumpur, Malaysia · Recruiting

  • University Malaya Medical Centre ( Site 0601)

    Kuala Lumpur, Malaysia · Recruiting

  • Sarawak General Hospital ( Site 0602)

    Kuching, Sarawak, Malaysia · Recruiting

  • IPOR Instituto Peruano de Oncología & Radioterapia ( Site 3400)

    Lima, Peru · Recruiting

  • Instituto Nacional de Enfermedades Neoplásicas ( Site 3401)

    Lima, Peru · Recruiting

  • Instituto Regional de Enfermedades Neoplasicas del Centro (IREN CENTRO) ( Site 3405)

    Concepción, Departamento de Junín, Peru · Recruiting

  • Clínica San Antonio ( Site 3404)

    Trujillo, La Libertad, Peru · Recruiting

  • National Cancer Centre Singapore ( Site 0800)

    Singapore, Central Singapore, Singapore · Recruiting

  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 2001)

    Madrid, Spain · Recruiting

  • Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 2000)

    L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting

  • CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2003)

    A Coruña, La Coruna, Spain · Recruiting

  • Clinica Universitaria Navarra - Madrid ( Site 2004)

    Madrid, Madrid, Comunidad de, Spain · Recruiting

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.